Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Dermatology

What Should I Be Screened for After Pyoderma Gangrenosum?

At a Glance

After a pyoderma gangrenosum diagnosis, doctors usually screen based on symptoms, history, and examination rather than ordering every test. They commonly consider inflammatory bowel disease, inflammatory arthritis, and blood disorders, while continuing routine preventive care.

When you are diagnosed with pyoderma gangrenosum (PG), your care team will evaluate you for other conditions that often accompany it. Research shows that many people with PG have an associated systemic (body-wide) condition, most commonly inflammatory bowel disease (IBD), inflammatory arthritis, or a blood disorder [1]. Because published studies look at different types of patients, the reported percentages vary and often overlap. It is also important to know that many people with PG have idiopathic disease, meaning no associated condition is ever found [2][3].

There is no one-size-fits-all testing protocol or universal “pan-screening” panel for PG [3]. Having PG does not mean you automatically need invasive procedures or whole-body cancer scans. Instead, doctors use a symptom-guided approach.

What is Usually Checked First?

Rather than running every possible test, your care team will typically start with:

  • A thorough medical history and review of your symptoms.
  • A physical exam, including checking your joints and skin.
  • Routine blood work, but only when clinically indicated.
  • Continued standard preventive care, including age- and sex-appropriate cancer screenings (like mammograms or routine colonoscopies), which should continue independently of your PG diagnosis.

Summary of Targeted Evaluations

Associated Condition Symptoms to Report Possible Initial Steps What is NOT Routinely Needed
Inflammatory Bowel Disease (IBD) Bloody/mucousy diarrhea, abdominal pain, frequent urgency, unexplained weight loss [4][5]. Review of symptoms, complete blood count (CBC), fecal calprotectin (a stool test checking for inflammation) [6][7]. Routine colonoscopy for everyone with PG who has no digestive symptoms [3].
Inflammatory Arthritis Joint swelling, prolonged morning stiffness, inflammatory back pain [8]. Joint physical exam, targeted imaging (X-rays) of painful joints [9][10]. Broad autoantibody blood panels if there are no joint symptoms [3].
Blood (Hematologic) Disorders Severe fatigue, recurrent fevers, drenching night sweats, easy bruising, feeling full quickly [11]. Routine complete blood count (CBC) to check for anemia or low platelets [9][12]. Routine bone marrow biopsy or serum protein electrophoresis for all PG patients [13].

Inflammatory Bowel Disease (IBD)

IBD, which includes ulcerative colitis and Crohn’s disease, is the most common condition linked to PG. Depending on the study, it affects about 17% to 41% of PG patients [1][14]. IBD is observed more frequently in PG patients under the age of 65 [14].

  • What your doctor looks for: Your doctor will ask if you have experienced abdominal pain, bloody or mucousy diarrhea, frequent urges to go to the bathroom, or unexplained weight loss [4][5].
  • Targeted evaluation: If you have gastrointestinal symptoms, or if blood tests show unexplained iron-deficiency anemia (low hemoglobin or hematocrit, which has many possible causes), your doctor may order specific tests. This might include a stool test like fecal calprotectin to check for intestinal inflammation, or a referral to a gastroenterologist [6][7]. When clinically indicated by your symptoms or test results, a gastroenterologist may perform a colonoscopy with biopsies to look for IBD. Stool testing or invasive bowel procedures are not universal screening tests for everyone with PG who lacks symptoms [6][3].

Inflammatory Arthritis

Inflammatory arthritis affects roughly 13% to 20% of people with PG, varying by study [1][14]. Unlike ordinary “wear-and-tear” osteoarthritis, inflammatory arthritis is an immune system condition and includes rheumatoid arthritis, psoriatic arthritis, and arthritis related to IBD [8].

  • What your doctor looks for: Joint issues often begin years before PG skin ulcers appear [8]. Your doctor will ask about joint swelling, prolonged morning stiffness, and inflammatory back pain.
  • Targeted evaluation: A careful history and joint examination are the most important tools. If your doctor suspects rheumatoid arthritis, they may order targeted blood tests to look for specific autoantibodies (proteins your immune system makes when it mistakenly targets your own tissues). However, there is no single blood test that reliably screens for or rules out psoriatic arthritis or IBD-associated arthritis [9][3]. A normal blood test does not mean you don’t have inflammatory arthritis, and if your joints are swollen or very stiff, your doctor may still refer you to a rheumatologist or order joint imaging [10]. Broad, unfocused autoimmune blood panels are generally not useful without specific joint symptoms [3].

Blood (Hematologic) Disorders

Blood-related conditions are found in roughly 5% to 9% of people with PG [1][14]. These conditions are observed more frequently in PG patients over the age of 65 [14] and those with the “bullous” (blistering) subtype of PG [15]. They include non-cancerous conditions like monoclonal gammopathy of undetermined significance (MGUS) and, less commonly, blood cancers like myelodysplastic syndrome (MDS) or leukemia [16].

  • What your doctor looks for: Your doctor will ask about general warning signs such as severe fatigue, unexplained recurrent fevers, drenching night sweats, easy bruising, or feeling full quickly (which can indicate an enlarged spleen) [11].
  • Targeted evaluation: A routine CBC may be used to check for abnormalities like low white blood cells, low platelets, or anemia [9][12]. Keep in mind that active PG, inflammation, and many common medications can affect blood counts. An abnormal CBC does not automatically mean you have cancer; your doctor will usually repeat the test or review your medications first. If symptoms or blood abnormalities persist, your doctor might order a serum protein electrophoresis test to check for MGUS—a condition that usually causes no symptoms and is simply monitored, as it is not a cancer [13]. Only if these initial, less invasive tests show concerning or persistent abnormalities will a hematologist (blood specialist) consider advanced testing, such as a bone marrow biopsy [11].

Ongoing Care and Follow-Up

For some people, an associated disease does not appear until after the PG skin lesions start. One observational study noted that when an associated condition developed after PG, it was frequently diagnosed within 24 months, particularly in patients under age 50 [17].

This is not a guarantee that something will develop, nor does it mean you need a strict schedule of repeating all tests. It simply highlights the importance of individualized, ongoing care. You should maintain regular follow-up appointments with your care team. If you develop new symptoms—such as persistent bloody stools, rapidly worsening joint swelling, or unusual bleeding—let your doctor know promptly so they can determine if targeted testing is needed.

Common questions in this guide

Which diseases are most often linked with pyoderma gangrenosum?
The conditions most often associated with pyoderma gangrenosum are inflammatory bowel disease, inflammatory arthritis, and blood disorders. Inflammatory bowel disease includes Crohn’s disease and ulcerative colitis; blood conditions can include a usually noncancerous protein abnormality called MGUS, or less commonly myelodysplastic syndrome and leukemia. Many people with PG have no associated condition.
Does a pyoderma gangrenosum diagnosis mean I need a colonoscopy?
Not necessarily. People with PG who have no digestive symptoms do not routinely need a colonoscopy. Persistent bowel symptoms or unexplained iron-deficiency anemia may lead to a stool test such as fecal calprotectin, a gastroenterology referral, and, when indicated, colonoscopy with biopsies.
How are inflammatory arthritis symptoms evaluated after PG?
Evaluation usually starts with questions about joint swelling, prolonged morning stiffness, and inflammatory back pain, followed by a joint examination. If these symptoms raise concern, a clinician may order targeted blood tests or joint imaging and refer you to a rheumatologist. A normal blood test does not rule out psoriatic arthritis or arthritis related to inflammatory bowel disease.
What blood testing is usually done for possible blood disorders after PG?
A complete blood count (CBC) is often the first test when a blood disorder is suspected because it can show anemia or low white blood cells or platelets. Active PG, inflammation, and medicines can change blood counts, so an abnormal result may be repeated and reviewed in context. Persistent abnormalities or concerning symptoms may lead to serum protein electrophoresis or, when warranted, a bone marrow biopsy.
Do I need cancer scans or invasive tests after a PG diagnosis?
PG does not automatically require a whole-body cancer scan, bone marrow biopsy, or other invasive testing. Continue routine cancer screening appropriate for your age and sex, such as mammograms or standard colonoscopies, and have additional tests only when symptoms or initial results support them. An abnormal CBC by itself does not prove cancer.
How long should I be monitored for associated conditions after PG?
Some associated conditions are diagnosed after the PG skin lesions begin, and one observational study found that many later diagnoses occurred within 24 months, especially in people younger than 50. This does not mean everyone will develop another disease or needs every test repeated on a fixed schedule. Keep regular follow-up and report new bowel, joint, fever, fatigue, or bleeding symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my medical history and physical exam, what specific baseline evaluations do you recommend for me?
  2. 2.Are any of the medications I am taking for my PG likely to cause changes in my blood counts or require routine monitoring?
  3. 3.Should I be referred to a gastroenterologist or rheumatologist based on the symptoms I have described?
  4. 4.What new or unexplained symptoms should prompt me to contact you between my regular appointments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis.

    Kridin K, Cohen AD, Amber KT

    American journal of clinical dermatology 2018; (19(4)):479-487 doi:10.1007/s40257-018-0356-7.

    PMID: 29721816
  2. 2

    Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum.

    Jiang YY, Li J, Li Y, et al.

    Chinese medical journal 2017; (130(22)):2674-2679 doi:10.4103/0366-6999.218004.

    PMID: 29133754
  3. 3

    Clinical Mimickers Misdiagnosed as Pyoderma Gangrenosum.

    Becker SL, Badawi AH, Thornton C, Ortega-Loayza AG

    American journal of clinical dermatology 2025; (26(4)):511-523 doi:10.1007/s40257-025-00941-z.

    PMID: 40155526
  4. 4

    Pyoderma Gangrenosum and inflammatory bowel disease: a combined medical and surgical approach - case report and literature review.

    Garieri P, Marcasciano M, Greto Ciriaco A, et al.

    European review for medical and pharmacological sciences 2022; (26(14)):5191-5199 doi:10.26355/eurrev_202207_29308.

    PMID: 35916817
  5. 5

    Hidden in Plain Sight: A Case Series of Inflammatory Bowel Disease With Dermatologic Lesions As Initial or Concurrent Manifestations.

    Obeidat K, Salim H, Malone JC, et al.

    Cureus 2024; (16(3)):e55548 doi:10.7759/cureus.55548.

    PMID: 38576673
  6. 6

    Pyoderma Gangrenosum as the First Manifestation of Inflammatory Bowel Disease: A Case Report.

    Nguyen NH, Tran TT, Khuc TT, et al.

    Case reports in gastrointestinal medicine 2026; (2026()):2028354 doi:10.1155/crgm/2028354.

    PMID: 41536753
  7. 7

    [Ulcerative colitis diagnosed with facial pyoderma gangrenosum: a case report].

    Ogata Y, Soeda A, Saura I, et al.

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2024; (121(6)):481-488 doi:10.11405/nisshoshi.121.481.

    PMID: 38853017
  8. 8

    Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.

    Sawka E, Zhou A, Latour E, et al.

    Clinical rheumatology 2021; (40(10)):3963-3969 doi:10.1007/s10067-021-05768-7.

    PMID: 34002351
  9. 9

    Pyoderma gangrenosum and cobalamin deficiency in systemic lupus erythematosus: a rare but non fortuitous association.

    Teoh SC, Sim CY, Chuah SL, et al.

    BMC rheumatology 2021; (5(1)):7 doi:10.1186/s41927-021-00177-4.

    PMID: 33653418
  10. 10

    Atypical Visceral Involvement of Pyoderma Gangrenosum.

    Ruiz NM, Ibarz JO, López SR, et al.

    Ochsner journal 2026; (26(3)):247-250 doi:10.31486/toj.25.0094.

    PMID: 42746439
  11. 11

    Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy.

    Jain A, Lad D, Prakash G, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2017; (33(2)):273-275 doi:10.1007/s12288-016-0713-8.

    PMID: 28596664
  12. 12

    Postoperative Pyoderma Gangrenosum Mimicking Early Periprosthetic Joint Infection After Total Hip Arthroplasty in a Patient With Hairy Cell Leukemia: A Diagnostic Challenge.

    Lehnert R, Schneider S, Walker B, Schrednitzki D

    Cureus 2026; (18(6)):e111606 doi:10.7759/cureus.111606.

    PMID: 42516484
  13. 13

    Monoclonal gammopathy in the setting of Pyoderma gangrenosum.

    Saeidi V, Garimella V, Shaji K, et al.

    Archives of dermatological research 2024; (316(6)):268 doi:10.1007/s00403-024-03098-7.

    PMID: 38795175
  14. 14

    The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.

    Ashchyan HJ, Butler DC, Nelson CA, et al.

    JAMA dermatology 2018; (154(4)):409-413 doi:10.1001/jamadermatol.2017.5978.

    PMID: 29450453
  15. 15

    Bullous pyoderma gangrenosum as a predictor of hematological malignancies.

    Vacas AS, Bollea-Garlatti ML, Torre AC, Galimberti RL

    Anais brasileiros de dermatologia 2018; (93(1)):133-134 doi:10.1590/abd1806-4841.20187031.

    PMID: 29641716
  16. 16

    Pyoderma gangrenosum in hematologic malignancies: A systematic review.

    Montagnon CM, Fracica EA, Patel AA, et al.

    Journal of the American Academy of Dermatology 2020; (82(6)):1346-1359 doi:10.1016/j.jaad.2019.09.032.

    PMID: 31560977
  17. 17

    Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.

    Vacas AS, Torre AC, Bollea-Garlatti ML, et al.

    International journal of dermatology 2017; (56(4)):386-391 doi:10.1111/ijd.13591.

    PMID: 28295267

This page is for informational purposes only and does not constitute medical advice. Your dermatologist and other clinicians should choose tests or referrals based on your symptoms, medical history, and examination.

Get notified when new evidence is published on Pyoderma gangrenosum.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.